Lauren Nicole Steimle

Lauren Nicole Steimle

Auto-generated profile, based on publicly available information

Lauren Nicole Steimle

H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
SBSanjay Basu
Sanjay Basu
JSJeremy B Sussman
Jeremy B Sussman
JRJoseph Rigdon
Joseph Rigdon
LSLauren Steimle
Lauren Steimle
BDBrian T Denton
Brian T Denton
RHRodney A Hayward
Rodney A Hayward
Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some serious adverse events. We sought to develop and validate risk models for predicting absolute risk difference (increased risk or decreased risk) for CVD events and serious adverse events from intensive BP therapy. A secondary aim was to test if the statistical method of elastic net regularization would improve the estimation of risk models for predicting absolute risk difference, as compared to a traditional backwards variable selection approach. Cox models were derived from SPRINT trial data and validated on ACCORD-BP trial data to estimate risk of CVD events and serious adverse events; the models included terms for intensive BP treatment and heterogeneous response to intensive treatment. The Cox models were then used to estimate the absolute reduction in probability of CVD events (benefit) and absolute increase in probability of serious adverse events (harm) for each individual from intensive treatment. We compared the method of elastic net regularization, which uses repeated internal cross-validation to select variables and estimate coefficients in the presence of collinearity, to a traditional backwards variable selection approach. Data from 9,069 SPRINT participants with complete data on covariates were utilized for model development, and data from 4,498 ACCORD-BP participants with complete data were utilized for model validation. Participants were exposed to intensive (goal systolic pressure < 120 mm Hg) versus standard (<140 mm Hg) treatment. Two composite primary outcome measures were evaluated: (i) CVD events/deaths (myocardial infarction, acute coronary syndrome, stroke, congestive heart failure, or CVD death), and (ii) serious adverse events (hypotension, syncope, electrolyte abnormalities, bradycardia, or acute kidney injury/failure). The model for CVD chosen through elastic net regularization included interaction terms suggesting that older age, black race, higher diastolic BP, and higher lipids were associated with greater CVD risk reduction benefits from intensive treatment, while current smoking was associated with fewer benefits. The model for serious adverse events chosen through elastic net regularization suggested that male sex, current smoking, statin use, elevated creatinine, and higher lipids were associated with greater risk of serious adverse events from intensive treatment. SPRINT participants in the highest predicted benefit subgroup had a number needed to treat (NNT) of 24 to prevent 1 CVD event/death over 5 years (absolute risk reduction [ARR] = 0.042, 95% CI: 0.018, 0.066; P = 0.001), those in the middle predicted benefit subgroup had a NNT of 76 (ARR = 0.013, 95% CI: −0.0001, 0.026; P = 0.053), and those in the lowest subgroup had no significant risk reduction (ARR = 0.006, 95% CI: −0.007, 0.018; P = 0.71). Those in the highest predicted harm subgroup had a number needed to harm (NNH) of 27 to induce 1 serious adverse event (absolute risk increase [ARI] = 0.038, 95% CI: 0.014, 0.061; P = 0.002), those in the middle predicted harm subgroup had a NNH of 41 (ARI = 0.025, 95% CI: 0.012, 0.038; P < 0.001), and those in the lowest subgroup had no significant risk increase (ARI = −0.007, 95% CI: −0.043, 0.030; P = 0.72). In ACCORD-BP, participants in the highest subgroup of predicted benefit had significant absolute CVD risk reduction, but the overall ACCORD-BP participant sample was skewed towards participants with less predicted benefit and more predicted risk than in SPRINT. The models chosen through traditional backwards selection had similar ability to identify absolute risk difference for CVD as the elastic net models, but poorer ability to correctly identify absolute risk difference for serious adverse events. A key limitation of the analysis is the limited sample size of the ACCORD-BP trial, which expanded confidence intervals for ARI among persons with type 2 diabetes. Additionally, it is not possible to mechanistically explain the physiological relationships explaining the heterogeneous treatment effects captured by the models, since the study was an observational secondary data analysis. We found that predictive models could help identify subgroups of participants in both SPRINT and ACCORD-BP who had lower versus higher ARRs in CVD events/deaths with intensive BP treatment, and participants who had lower versus higher ARIs in serious adverse events.

11 March 2017
Verified
Book Chapter
Closed access
PDF file
LSLauren N. Steimle
Lauren N. Steimle
BDBrian T. Denton
Brian T. Denton

10 May 2021 in IISE Transactions
Verified
Journal Article
Closed access
LSLauren N. Steimle
Lauren N. Steimle
DKDavid L. Kaufman
David L. Kaufman
BDBrian T. Denton
Brian T. Denton
Markov decision processes (MDPs) have found success in many application areas that involve sequential decision making under uncertainty, including the evaluation and design of treatment and screening protocols for medical decision making. However, the data used to parameterize the model can influence what policies are recommended, and multiple competing data sources are common in many application areas, including medicine. In this article, we introduce the Multi-model Markov decision process (MMDP) which generalizes a standard MDP by allowing for multiple models of the rewards and transition probabilities. Solution of the MMDP generates a single policy that maximizes the weighted performance over all models. This approach allows the decision maker to explicitly trade-off conflicting sources of data while generating a policy of the same level of complexity for models that only consider a single source of data. We study the structural properties of this problem and show that it is at least NP-hard. We develop exact methods and fast approximation methods supported by error bounds. Finally, we illustrate the effectiveness and the scalability of our approach using a case study in preventative blood pressure and cholesterol management that accounts for conflicting published cardiovascular risk models.

25 February 2022 in Socio-Economic Planning Sciences
Verified
Journal Article
Closed access
LSLauren N. Steimle
Lauren N. Steimle
YSYuming Sun
Yuming Sun
LJLauren Johnson
Lauren Johnson
TBTibor Besedeš
Tibor Besedeš
PMPatricia Mokhtarian
Patricia Mokhtarian
DNDima Nazzal
Dima Nazzal

1 January 2024 in Manufacturing & Service Operations Management
Verified
Journal Article
Closed access
GGGian-Gabriel P. Garcia
Gian-Gabriel P. Garcia
LSLauren N. Steimle
Lauren N. Steimle
WMWesley J. Marrero
Wesley J. Marrero
JSJeremy B. Sussman
Jeremy B. Sussman
Problem definition: Effective hypertension management is critical to reducing the consequences of atherosclerotic cardiovascular disease, a leading cause of death in the United States. Clinical guidelines for hypertension can be enhanced using decision-analytic approaches capable of capturing complexities in treatment planning. However, model-generated recommendations may be uninterpretable/unintuitive, limiting their clinical acceptability. We address this challenge by investigating interpretable treatment plans. Methodology/results: We formulate interpretable treatment plans as Markov decision processes (MDPs) and analyze the problems of optimizing monotone policies, which prohibit decreasing treatment intensity for sicker patients, and class-ordered monotone policies, which generalize monotone policies. We establish that both policies depend on initial state distributions and that optimal monotone policies can be generated tractably for many treatment planning problems. Next, we propose exact formulations for optimizing interpretable policies broadly. Then, we analyze the price of interpretability, proving that the class-ordered monotone policy’s price of interpretability does not exceed the monotone policy’s price of interpretability. Finally, we formulate and evaluate MDPs for hypertension treatment planning using a large nationally representative data set of the U.S. population. We compare the structure and performance of optimal monotone policies and class-ordered monotone policies with optimal MDP-based policies and current clinical guidelines. At the patient level, optimal MDP-based policies may be unintuitive, recommending more aggressive treatment for healthier patients than sicker patients. Conversely, monotone policies and class-ordered monotone policies never deescalate treatment, reflecting clinical intuition. Across 66.5 million patients, optimized monotone policies and class-ordered monotone policies outperform clinical guidelines, saving over 3,246 quality-adjusted life years per 100,000 patients, with both policies paying a low price of interpretability. Sensitivity analysis illustrates that monotone policies and class-ordered monotone policies are robust to various definitions of “interpretability.” Managerial implications: Interpretable policies can be tractably optimized, drastically outperform existing guidelines, and perform near optimally—potentially increasing the acceptability of decision-analytic approaches in practice. Funding: L. N. Steimle and W. J. Marrero received support from the National Science Foundation Graduate Research Fellowship [Grant DGE 1256260]. J. B. Sussman received support from the National Institutes of Health [Grants R01NS102715 and RF1AG068410], the U.S. Department of Veterans Affairs [Grants 1I01-HX003304 and 1I50-HX003251], and the Michigan Department of Health and Human Services. Supplemental Material: The e-companion is available at https://doi.org/10.1287/msom.2021.0373 .

8 March 2021 in IISE Transactions
Verified
Journal Article
Closed access
LSLauren N. Steimle
Lauren N. Steimle
VAVinayak S. Ahluwalia
Vinayak S. Ahluwalia
CKCharmee Kamdar
Charmee Kamdar
BDBrian T. Denton
Brian T. Denton
We consider the problem of decision-making in Markov decision processes (MDPs) when the reward or transition probability parameters are not known with certainty. We study an approach in which the decision maker considers multiple models of the parameters for an MDP and wishes to find a policy that optimizes an objective function that considers the performance with respect to each model, such as maximizing the expected performance or maximizing worst-case performance. Existing solution methods rely on mixed-integer program (MIP) formulations, but have previously been limited to small instances, due to the computational complexity. In this article, we present branch-and-cut and policy-based branch-and-bound (PB-B&B) solution methods that leverage the decomposable structure of the problem and allow for the solution of MDPs that consider many models of the parameters. Numerical experiments show that a customized implementation of PB-B&B significantly outperforms the MIP-based solution methods and that the variance among model parameters can be an important factor in the value of solving these problems.